| abstract |
In accordance with the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder enhanced by the inhibition of the A1-A2b receptor or, in particular, of the A2a receptor wherein the compound of formula A1 it has the structure (see formula) where A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, whose group Cy1 is optionally substituted by one or more R4a substituents; HetA represents a 5-14 membered heterocyclic group that can be aromatic, completely saturated or partially unsaturated, and that contains one or more heteroatoms selected from O, S and N, whose heterocyclic group may comprise one, two or three rings and whose group HetA is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3 to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whose group Cy2 is optionally substituted by one or more R4c substituents; HetB represents a 3 to 10 membered heterocyclic group that can be aromatic, completely saturated or partially unsaturated, and that contains one or more heteroatoms selected from O, S and N, whose heterocyclic group may comprise one or two rings or whose HetB group is optionally substituted by one or more R4d substituents. |